The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Sibutramine Produces Dose‐Related Weight Loss
Abstract
BRAY, GEORGE A., GEORGE L. BLACKBURN, JAMES M. FERGUSON, FRANK L. GREENWAY, ADESH K. JAIN, CARL M. MENDEL, JOSEPH MEN‐DELS, DONNA H. RYAN, SHERWYN L. SCHWARTZ, MONTE L. SCHEINBAUM, AND TIMOTHY B. SEATON. Sibutramine produces dose‐related weight loss.Obes Res. Objective Sibutramine is a weight control drug that inhibits the reuptake of both serotonin and norepinephrine. In animals, it reduces food intake and increases thermogenesis and preliminary data in human beings showed weight loss. This paper reports a 24‐week dose‐ranging study to determine the effect of sibutramine on body weight of patients with obesity. Research Methods and Procedures Seven clinical centers screened 1463 patients with obesity and randomized 1047 to 24 weeks of treatment with 1 of 6 doses of sibutramine (1, 5, 10, 15, 20, or 30 mg) or placebo once daily. Six hundred eighty‐three patients completed the study. A two‐week placebo run‐in period was used to initiate a standardized program of diet, physical activity, and lifestyle changes. Results Weight loss was dose‐related and statistically significant vs. placebo (p<0.05) across all time‐points for a 5 mglday to 30 mglday dosage of sibutramine. At week 24, percent weight loss from baseline for completers was: placebo, 1.2%; 1 mg, 2.7%; 5 mg, 3.9%; 10 mg, 6.1%; 15 mg, 7.4%; 20 mg, 8.8%; and 30 mg, 9.4%. Weight loss achieved at week 4 was predictive of weight loss achieved at week 24. Patients losing weight demonstrated an increase in serum high density lipoprotein cholesterol and reductions in serum triglycerides, total cholesterol, low density lipoprotein cholesterol, and uric acid. Small mean increases in blood pressure and pulse rate (with considerable individual variability) were observed in patients treated with sibutramine. The most frequent adverse events were dry mouth, anorexia, and insomnia. Discussion Sibutramine administered once daily for 24 weeks in the weight loss phase of treatment for uncomplicated obesity produced dose‐related weight loss and was well tolerated. Improvements in serum lipids and uric acid accompany sibutramine‐induced weight loss. Most of the adverse events observed on sibutramine are related to its pharmacology, including small mean increases in blood pressure and heart rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Kuczmarski, R. J. (1994) · JAMA · doi:10.1001/jama.272.3.205 · Cited by 2,362
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Beneficial health effects of modest weight loss.
Dj, G. (1992) · PubMed · Cited by 1,263
Williamson, D. F., Pamuk, E., Thun, M., Flanders, D., Byers, T., & Heath, C. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117386 · Cited by 527
INTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY
Guy-Grand, B., Crepaldi, G., Vre, P., Apfelbaum, M., Gries, A., & Turner, P. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91499-2 · Cited by 309
Weighing the Options: Criteria for Evaluating Weight-Management Programs
Thomas, P. (2013) · Cited by 285
Long-term Weight Loss With Sibutramine: A Randomized Controlled Trial
Wirth, A., & Krause, J. (2001) · JAMA · doi:10.1001/jama.286.11.1331 · Cited by 272
Mason, E. E. (1992) · Obesity Surgery · doi:10.1381/096089292765560187 · Cited by 238
Comparison of continuous and intermittent anorectic therapy in obesity.
Munro, J. F., MacCuish, A. C., Wilson, E. M., & Duncan, L. J. (1968) · BMJ · doi:10.1136/bmj.1.5588.352 · Cited by 215
Cited by
Plasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241
The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It
The Look AHEAD Research Group (2006) · Obesity · doi:10.1038/oby.2006.84 · Cited by 873
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Appropriate Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults
JAKICIC (CHAIR), J. M., CLARK, K., COLEMAN, E., DONNELLY, J. E., FOREYT, J., MELANSON, E., VOLEK, J., & VOLPE, S. L. (2001) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200112000-00026 · Cited by 752
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544
Metadata
- Authors
- Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., & Seaton, T. B.
- Venue
- Obesity Research
- Publisher
- Wiley
- Published
- 1999-03
- Volume
- 7
- Issue
- 2
- Pages
- 189-198
- ISSN
- 1071-7323 (ISSN-L)
- 1550-8528
- OpenAlex
- W1965483352
- Cited by
- 382
- References
- 28
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sibutramine Produces Dose‐Related Weight Loss. https://app.cochat.ai/papers/10.1002/j.1550-8528.1999.tb00701.x
- The paper
- Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., & Seaton, T. B. (1999). Sibutramine Produces Dose‐Related Weight Loss. Obesity Research. https://doi.org/10.1002/j.1550-8528.1999.tb00701.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.